Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Revenue · Q4 FY2026 · quarter ended Sep 2026

Revenue declines year over year

Q4 FY2026 revenue of $37.79M fell 85.3% year over year, behind the -45.6% change in trailing-twelve-month revenue. Sequentially, it fell 49.8% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of $306.26M (-32.1%) for the fiscal year ending Sep 2027, a step up from the -45.6% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$37.79M-49.8% QoQ
Last fiscal yearSep 2026
$450.82M-45.6% YoY
LTMSep 2026
$450.82M-45.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-85.3%-83.9%+1.4 pp
1 year-45.6%-32.1%+13.6 pp
3-year CAGR+23.3%+30.2%+7.0 pp
5-year CAGR+44.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2026
450.82M USD
Year-over-year change
-45.6%
4-year CAGR
+16.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -45.6% is the 5th highest of 6, against a peer median of -29.2%.
  • Over three fiscal years its annual growth of +23.3% compares with a peer median of +35.1%.
ARWR Competitors
Revenue for ARWR and competitors
Company Period LTM YoY 3-year CAGR
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$4.8B USD+95.1%+53.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$959.76M USD-0.7%+17.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$450.82M USD-45.6%+23.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$71.8M USD-31.6%+127.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$45.35M USD-66.4%-31.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026€13.44M EUR-29.2%+62.0%
SLNSilence Therapeutics plcLTM Mar 2026$921.49K USD—-68.4%
Peer median (excluding ARWR) —-29.2%+35.1%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.